Sofinnova Partners Leads SafeHeal’s €6 Million Series a Financing Round
SafeHeal, an early-stage medtech company specialized in digestive surgery and focused on the development of the Colovac device, announces today that it has closed a €6 million Series A financing round led by Sofinnova Partners.
Based in Paris, SafeHeal develops an innovative digestive anastomosis protection device, called Colovac, designed to reduce complications and obviate the need for ostomies for colectomy patients. This technology consists of a minimally invasive and fully reversible implant that remains in place until the body’s natural healing and tissue repair processes are complete, for approximately two weeks, after which it is removed. SafeHeal’s device has the potential to radically transform the market while significantly improve patients’ quality of life by enabling them to resume their normal life without having to bear an artificial anus and wear ostomy pouches for several months. About 270,000 colectomy patients receive an ostomy every year in Europe and the USA, representing an initial market greater than 1 billion €.
Funds raised will allow to execute SafeHeal’s clinical and regulatory market access program, followed by a focused commercial launch. The company has already begun a CE mark study and has successfully tested the device on seven patients. Attesting of its disruptive potential, SafeHeal is laureate of the Worldwide Innovation Challenge 2015 edition.
SafeHeal was founded in 2015 by MD Start, a medtech accelerator founded by Sofinnova Partners in 2008 and specialized in building companies focusing on large, unaddressed clinical needs and significant market opportunities. Prior to leading this Series A financing round, Sofinnova Partners participated to SafeHeal’s seed funding, together with MD Start.
“This investment enables us to execute our aggressive clinical and regulatory strategy, launch commercial operations once CE mark will be received and also continue investing in our R&D. We are currently recruiting patients in our First-in-Human clinical trial in France and are planning to extend the enrollment to hospitals in Germany, the UK and the US”, said Karl Blohm, CEO of SafeHeal.
“SafeHeal is a great example of the high impact therapies we are focusing on” said Anne Osdoit, Partner at MD Start and co-founder of SafeHeal, “We are thrilled to see SafeHeal maturing into its next development phase. This financing round allows them to engage in the transformation from incubation status to commercial operations”.
“We are excited to invest in SafeHeal and believe that their endoluminal bypass sheath is the most innovative disruption in the protection of colorectal anastomosis”, said Antoine Papiernik, Managing Partner at Sofinnova Partners, “This investment also demonstrates the power of our strategy allowing us to be present from incubation, with MD Start building companies from the ground up, to much larger rounds of funding to create potential worldwide leaders in their space”.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Diamond CBD, POTN Subsidiary, Enters the $46 Billion Coffee Market With the Release of Premium Line of CBD-Infused Coffee & Tea K-Kup Capsules14.12.2018 15:42 | Pressemelding
Diamond CBD Inc., wholly owned subsidiary of PotNetwork Holdings, Inc. (OTC Pink: POTN), a leader in hemp extraction and innovative CBD products for the wellness market, enters the Coffee segment, an industry expected to reach revenues of $46 Billion in 2018. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181214005308/en/ Experience a cup of Chill (Photo: Business Wire) Produced in accordance with a universal K-Cup design, these pods fit in almost all modern single cup coffee makers, making it an easily integrated enhancement to any environment, delivering 25mgs of CBD in a tasty favorite beverage at less than $5 per cup. This new line of premium Chill Coffee Capsules was recently added to the Company’s broad range of cannabinoid and natural hemp products. Each box comes with 4 individual capsules in original chill coffee, decaf chill coffee, chill black tea, and chill green tea flavors. The unit price for each box is $10.00
Henley & Partners Enlarges Executive Committee to Manage Expansion and Growth14.12.2018 14:00 | Pressemelding
Residence- and citizenship-by-investment programs have firmly established themselves over the past few years as the new frontier in terms of freedom, flexibility, and future-readiness, both for the countries issuing these programs and for the individual investors participating in them. The societal and economic value these programs generate is undisputed. The investment migration industry as a whole is currently grossing roughly USD 18 billion per year, with an expectation that it will hit the USD 20 billion mark very soon. Foreign direct investment (FDI) is now considered the lifeblood of economic growth for many developing and recovering smaller countries around the world. As such, the number of investment migration programs has been increasing rapidly, from just a handful of programs in the 1980s and 1990s to over 100 countries that now have investment migration provisions in their laws. There are more than 60 active programs today, with Moldova and Montenegro — both fast-growing Eu
Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer14.12.2018 09:07 | Pressemelding
Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The study consists of three cohorts, two of which allow for prior treatment with immune checkpoint inhibitors (ICIs) either in combination with chemotherapy in the first-line or as monotherapy in the second-line of treatment. The interim results from Cohort B (first-line chemotherapy, second-line immune checkpoint inhibitors, third-line Vargatef® plus docetaxel) were presented today at ESMO Immuno-Oncology Congress 2018 in Geneva.1 Despite a limited sample size, the VARGADO study adds to the body of evidence for nintedanib in lung adenocarcinoma following pre-treatment with chemotherapy and ICIs.1,3 The addition of nintedanib to docetaxel ha
Alps Electric to Exhibit at CES 2019 as Alps Alpine for the First Time14.12.2018 07:58 | Pressemelding
Japanese comprehensive electronic components manufacturer Alps Electric Co., Ltd. (TOKYO:6770) (Ota-ku, Tokyo; President: Toshihiro Kuriyama) will exhibit at CES 2019, to open at the Las Vegas Convention and World Trade Center in Las Vegas, Nevada, in the United States on January 8. Alps Electric will be taking part as a new company, Alps Alpine Co., Ltd., for the first time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213006022/en/ Alps Alpine's new touch input device for automotive (Graphic: Business Wire) At CES 2019, an exposition of cutting-edge technologies brought together from around the world, Alps Electric will present a variety of technologies in response to the major trends in automotive development referred to as “CASE”—namely connected cars, autonomous driving, sharing and services, and electric vehicles. Making its first appearance at the show as a new company following its business integration with subs
Kalray Joins Autoware Foundation as Founding Premium Member14.12.2018 07:18 | Pressemelding
Kalray (Euronext Growth Paris – ALKAL), a pioneer in processors for new intelligent systems, today announced it has joined the Autoware Foundation as a founding premium member. The formation of Autoware was formally announced on December 10, 2018 with a mission of facilitating the deployment of Autoware open-source projects enabling self-driving mobility. The Autoware Foundation creates synergies between corporate development and academic research, enabling autonomous driving technology for everyone. "We are glad to have the presence of Kalray as a premium member of the Autoware Foundation. Having highly efficient hardware solutions supporting autonomous driving software is instrumental to boost the deployment of Autoware in the market!" said Shinpei Kato, member of the Board of Directors for Autoware. Autonomous driving demands massive processing power, low power consumption and bulletproof safety and security to handle critical functions like AI processing, acceleration of perception
IDEMIA Provides Subscription Management Platform to dtac in Thailand to Offer eSIM Connected Watches to All Its Subscribers.14.12.2018 03:30 | Pressemelding
IDEMIA, the global leader in Augmented Identity, has been selected by dtac, the leading mobile operator in Thailand, to offer connectivity on eSIM connected watches. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181213005934/en/ Credits : IDEMIA IDEMIA’s Subscription Management platform (or remote SIM provisioning) is the technology that remotely connects the embedded SIM of a smartwatch to dtac’s network without inserting a physical SIM card. Indeed, the IDEMIA Subscription Manager is a server which securely manages the lifecycle of mobile subscriptions and profiles for eSIM-ready consumer devices and wearables. This solution is compliant with the latest GSMA (Global System for Mobile Communications Association) standards to ensure global interoperability and, thanks to the scalability of the platform, the operator will be able to serve up to millions of customers during peak times. dtac subscribers now have the possibilit